Fiche publication
Date publication
novembre 2024
Journal
BMC biology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges
,
Dr BURCKEL Hélène
Tous les auteurs :
Bou-Gharios J, Noël G, Burckel H
Lien Pubmed
Résumé
Glioblastoma multiforme (GBM) is the most common adult primary brain tumor. The standard of care involves maximal surgery followed by radiotherapy and concomitant chemotherapy with temozolomide (TMZ), in addition to adjuvant TMZ. However, the recurrence rate of GBM within 1-2 years post-diagnosis is still elevated and has been attributed to the accumulation of multiple factors including the heterogeneity of GBM, genomic instability, angiogenesis, and chronic tumor hypoxia. Tumor hypoxia activates downstream signaling pathways involved in the adaptation of GBM to the newly oxygen-deprived environment, thereby contributing to the resistance and recurrence phenomena, despite the multimodal therapeutic approach used to eradicate the tumor. Therefore, in this review, we will focus on the development and implication of chronic or limited-diffusion hypoxia in tumor persistence through genetic and epigenetic modifications. Then, we will detail the hypoxia-induced activation of vital biological pathways and mechanisms that contribute to GBM resistance. Finally, we will discuss a proteomics-based approach to encourage the implication of personalized GBM treatments based on a hypoxia signature.
Mots clés
Glioblastoma multiforme, HIF-1α, HIF-2α, Hypoxia, Proteomics
Référence
BMC Biol. 2024 11 28;22(1):278
